Bengaluru/Mumbai, Nov. 22 -- Sensing a boom in GLP-1 therapies in India, diagnostic chains are racing to build the clinical backbone for what could be the country's next major shift in metabolic health. GLP-1 drugs-glucagon-like peptide-1 agonists-mimic a natural hormone that helps regulate appetite, insulin release and blood sugar, and are rapidly reshaping global obesity and diabetes care.

With India now seeing the arrival of Mounjaro and Wegovy, and cheaper generics expected once semaglutide goes off patent, top labs are curating specialized programmes to track cardiac, liver, pancreatic and metabolic markers for patients starting these treatments. Their bet: as GLP-1 therapy expands from diabetics to the broader obesity segment, diag...